Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 88 of 113, showing 5 Applications out of 564 total, starting on record 436, ending on 440

# Protocol No Study Title Investigator(s) & Site(s)

436.

ECCT/25/01/01   FLORAL
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
2. Gertrude’s Children’s Hospital (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
View

437.

ECCT/25/12/05   Floral Study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study             
Principal Investigator(s)
1. Janet Oyieko
Site(s) in Kenya
1. Kombewa Clinical Research Center (Kisumu county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. Gertrude\'s Children\'s Hospital (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
View

438.

ECCT/19/04/03   Phase III pediatric study with the L-PZQ ODTs
    An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®)   
Principal Investigator(s)
1. Maurice Reuben Odiere
Site(s) in Kenya
KEMRI-Centre for Global Health Research (CGHR)
 
View

439.

ECCT/12/08/01   Partners Demonstration Project
    An open-label, pilot demonstration and evaluation project of antiretrovira-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples.   
Principal Investigator(s)
1. Dr. Nelly Rwamba Mugo
Site(s) in Kenya
1. Partners in Prevention, Thika Site (Kiambu county)
2. Partners in Prevention, Kisumu Site (Kisumu county)
 
View

440.

ECCT/13/03/02   An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples
    An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples The Partners PrEP Study Demonstration Project   
Principal Investigator(s)
1. DR.ELIZABETH ANNE BUKUSI ELIZABETH ANNE BUKUSI
Site(s) in Kenya
1. THIKA (Nairobi City county)
 
View